Pathway Genomics Remains In FDA Crosshairs For Genetic Testing Service
This article was originally published in The Gray Sheet
Executive Summary
An untitled letter from FDA targets Pathway Genomics' recent launch of a cancer screening assay that FDA says is being marketed directly to consumers without proper FDA review.